A share price of Genmab ADR [GMAB] is currently trading at $23.71, up 0.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GMAB shares have gain 1.32% over the last week, with a monthly amount drifted -11.96%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On August 20, 2024, downgrade downgraded it’s rating to Neutral. RBC Capital Mkts upgraded its rating to a Outperform. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $48 on February 23, 2024. Citigroup downgraded its rating to Sell for this stock on January 22, 2024. In a note dated December 06, 2023, UBS upgraded an Buy rating on this stock.
Genmab ADR experienced fluctuations in its stock price throughout the past year between $23.24 and $35.88. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $23.71 at the most recent close of the market. An investor can expect a potential return of 81.36% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Trailing Twelve Months sales for Genmab ADR [NASDAQ:GMAB] were 2.75B which represents 27.12% growth. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.39%, and Net Profit Margin reading is 0.29%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.17 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.56 points at the first support level, and at 23.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.80, and for the 2nd resistance point, it is at 23.89.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Genmab ADR [NASDAQ:GMAB] is 5.03. Also, the Quick Ratio is 5.02, while the Cash Ratio stands at 0.99. Considering the valuation of this stock, the price to sales ratio is 5.48, the price to book ratio is 3.38 and price to earnings (TTM) ratio is 19.46.
